The Utah-based company has made its Logix Smart 2019-nCoV polymerase chain reaction (PCR) tests immediately available on a research use only (RUO) basis to thousands of laboratories throughout the world.
"We believe the way that Co-Diagnostics can be most helpful in this ongoing situation is by providing diagnostic solutions that are affordable and accessible in any market in the world,” CEO Dwight Egan said last week.
READ: Co-Diagnostics to showcase rapid coronavirus response at infectious disease conference in DC, closes on $10.2M offering
The coronavirus, which originated in Wuhan, China, has killed at least 1,873 people and infected more than 72,000, according to CNN.
“Our mandate includes supporting as many markets as possible in a public health crisis, and taking a test from design to commercialization in under three weeks underscores this commitment. Doing so also provides a compelling proof-of-concept that the company’s unique process and patented technology could quickly and efficiently be applied to address the diagnostic needs associated with other emergencies, including potential mutations of the coronavirus."
The company is also in discussions with regulators to gain clearance for use as an Investigational New Drug, which it believes will open doors in additional markets, including sales within the US.
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel